Global Biosimilars Market Overview

Biosimilars Market was valued at USD 9630 million in 2021 and is expected to reach USD 55410 million by the year 2028, at a CAGR of 28.4%.

Biosimilar is a biological medicinal product also referred to as follow-on biologic or coming entry biologic. It is the same copy of an initial product produced by a diverse company. It is a reliably authorized version of original and innovative products and produced only when the original product's patent expires. Biosimilar alternatively known as bio-pharmaceuticals or follow-on biologics, biosimilars vary from generics in the whole production process, right from the raw materials used in their production. Biosimilar is a biological product highly similar to a biologic i.e., reference products; nevertheless, not identical to it. Biosimilars are not generics and are never cured as generics by key players and suppliers. Generally obtained from plants, animals, bacteria, yeast, and viruses, biosimilars are manufactured basically by the two key processes, controlled gene expression, and recombinant DNA technology. Rising consciousness and incorporation of biosimilars have been growing since the past few years, arising in a flourishing market for biosimilars. Moreover, the European region is a considerable growth for the biosimilars market. Nevertheless, North America, especially the U.S., has recently taken a notable speed.

Market Dynamics and Factors for the Biosimilars Market:

Drivers:

As biosimilars are extensively utilized in the prevention and cure of a range of chronic diseases, such as diabetes, growth hormone deficiency, cancers, CVDs, hematological diseases, autoimmune diseases, kidney failure, rheumatoid arthritis, and infectious diseases, the demand for biosimilars is probably to collect momentum within the next few years. The increasing geriatric population is another major factor identified to primarily turn the growth of the biosimilars market.
Furthermore, rising gaining preference over conventional biologics imputed to relatively lesser costs compared to that of their parent biological drugs. Various government and private bodies are increasingly encouraging the utilization of biosimilars over conventional biologics and synthetic drug products. This will remain a key factor accelerating the market for biosimilars. High costs of existing biological drugs and the significantly rising pharmaceutical realm will collectively trigger the market for biosimilars.
Similar to the pharmaceutical industry, the related biosimilar markets are also reaching traction owing to the increased activities which are encouraging the use of substitutes medications. In line with the active investments and research into the biopharmaceuticals segment, the adjacent biosimilar market is expected to tackle significant profits shortly. This is examined as a marketing strategy to raise the frequency of biosimilars instead of conventional biological medicines. With this move, the companies are focusing on emerging countries that are anticipated to attract a significant customer base which leads to the growth for the biosimilar market over the forecast period.

Restraints:

High production costs and complexity may remain longstanding roadblocks to mainstream manufacturing of biosimilars. Furthermore, the accessibility of affordable generic drugs in the market may also restraint the sales of biosimilars. The key factor for the restraint for producers is to set up the biosimilarity by huge analytical characterization. Before approval, each biosimilar can undergo inspection by respective regulatory bodies to prove the similarity in terms of safety and efficacy. Furthermore, consistent price decline and the resultant price-competitiveness in the market will be the durable challenges to the commercialization of biosimilars over the forecast period.

Opportunities:

Patent expiry of blockbuster biotech drugs and research on latest indications. Most recent biologic drugs lost their patent protection in the first half of the 20th century, while many of the current best-selling drugs are set to lose their patent protection in the future years. This is producing new opportunities for biosimilar drugs. By 2023, patents of nearly 20 oncology biologics will cease, which could lead to more biosimilars in the field of oncology. Currently, accessible biosimilars are utilized to cure an extensive range of diseases and disorders, incorporating cancer, rheumatoid arthritis, kidney failure, infectious disorders, psoriasis, anemia, type 1 and type 2 diabetes, post-menopausal osteoporosis, and growth hormone disorders. The major focus therapeutic areas for which various biosimilars are in the pipeline include diabetes, oncology, autoimmune disorders, and hepatitis. Besides these, biosimilars can be produced for other chronic disorders, such as breast cancer, meningitis, hepatitis E adult T-cell leukemia, hypertension, and obesity.

Market Segmentation

Based on product, the biosimilars market is classified into recombinant non-glycosylated proteins and recombinant glycosylated proteins. Recombinant non-glycosylated proteins are further categorized into human growth hormones, granulocyte colony-stimulating factors, interferons, and insulin. Recombinant glycosylated proteins are next categorized into erythropoietin, monoclonal antibodies, and follitropin. The recombinant non-glycosylated proteins segment is projected to witness the maximum market growth over the forecast period. Recent technological developments in cell technology and high-throughput analytical methods will support enable efficient production of recombinant non-glycosylated proteins resulting in improved sales.
Based on application, the biosimilars market is classified into growth hormonal deficiency, blood disorders, chronic and autoimmune disorders, oncology, and others. The oncology segment is projected to registered maximum biosimilars market share throughout the forecast period. The factors that can be attributed to the growth of the segment are related to the high frequency of cancer including blood cancer, lung, breast, liver, colorectal, and stomach. As per the Globocan 2020, the incidence of the latest cancer patients was expected to be 19,292,789 in 2020, with about 9,958,133 deaths owing to cancers. In addition, the new cancer incidence is anticipated to reach 30.2 million by 2040, according to the international agency for research on cancer (IARC). Recent approvals of a biosimilar for cancer treatment and a large number of oncology products in the pipeline are also accelerating the segment growth.

Players Covered in Biosimilars market are :

• Novartis AG (Switzerland)
• Pfizer Inc. (US)
• Dr. Reddy’s Laboratories Ltd. (India)
• Amgen Inc. (US)
• Eli Lilly and Company (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Fresenius SE & Co. KGaA (Germany)
• STADA Arzneimittel AG (Germany)
• Boehringer Ingelheim (Germany)
• Gedeon Richter PLC (Hungary)
• Celltrion (South Korea)
• Samsung Biologics (South Korea)
• Coherus BioSciences (US)
• Biocon Limited (India)
• Viatris Inc. (US)
• Amega Biotech (Argentina)
• Apotex Inc. (Canada)
• Biocad (Russia)
• mAbxience (Spain)
• Probiomed S.A. De C.V. (Mexico)
• Fujifilm Kyowa Kirin Biologics Co. Ltd. (Japan)
• Intas Pharmaceuticals Ltd. (India)
• Thermex (UK)
• Reliance Life Sciences (India)
• Kashiv Biosciences (US) and other major players.

Regional Analysis for the Biosimilars Market:

The North American region is expected to dominate the biosimilars market during the forecast period. The major factors turning the growth of the studied market in the region include the high incidence of chronic diseases, such as cancers, along with the raised funding in research and development activities by the key players. In addition, North America is the hub for a large number of key players in the biosimilars market, such as Pfizer, Inc. (US), Coherus BioSciences (US), Kashiv Biosciences (US), and Viatris, Inc. (the US), among others. The rising pipeline of products and latest product introduction has risen the biosimilars market growth in the region. For example, in June 2020, Pfizer Inc. gained the FDA approval for its pegfilgrastim biosimilar, Nyvepria, indicated for application in declining the incidence of infection. Therefore, because of the high incidence of chronic diseases, such as cancers, and increasing R&D activities, the market is anticipated to stimulate significantly during the forecast period in North America.
Asia Pacific region is expected to register a significant biosimilars market share owing to the presence of various emerging players in the region. In addition, the high geriatric population in the region is related to the high healthcare expenditure burden; and the market segment demands lower-cost substitutes such as Biosimilars.
Europe region is anticipated to grow due to the favorable regulatory scenario and healthy presence of market players in the region. Growth in these markets is especially turned by different factors, such as the impending patent expiry of biologic products and the introduction of new biosimilars, the growing incidence of chronic disorders, the development of new players, and early entry into the market.

Key Industry Developments in the Biosimilars Market:

• In April 2021, Novartis AG (Sandoz) marked an agreement with Bio-Thera Solutions (China) to commercialize BAT1706 (proposed bevacizumab biosimilar by Bio-Thera Solutions) in the US, Canada, Europe, and other international markets.
• In July 2021, Biocon Ltd (Biocon Biologics) collaborated with Viatris, Inc. received FDA approval for the first interchangeable biosimilar SEMGLEE (insulin glargine-yfgn injection) for the curing of diabetes.

COVID-19 Impact on the Biosimilars Market:

The COVID-19 pandemic adversely affected the biosimilars market and it has imposed a great challenge to the pharmaceutical companies targeted on biosimilar growth. The decline in the FDA authorization of non-COVID therapeutics during the current pandemic is anticipated to delay the process of product approvals and launches, thereby, hampering the biosimilars market growth. In addition, as most of the clinical trials have been carried over to fight the COVID-19 situation and decrease the infection among participants, most of the pipeline products are revealing a slow pace of research and development activities. Moreover, the World Health Organization (WHO) announced COVID-19 as a pandemic on March 11, 2020. There has been a huge amount of effort put into emerging new treatments and vaccines to treatment against infection. Within a few weeks of research, companies began coming up with drugs and treatments to cure the infection.   Additionally, owing to the shutdowns and travel bans over the globe, there is a scarcity in supply chain and raw materials, which would influence biosimilar production. Therefore, owing to these factors, COVID-19 has had a great impact on the biosimilar market over the period.

Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Type
 3.2 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  3.5.1 Drivers
  3.5.2 Restraints
  3.5.3 Opportunities
  3.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 4: Biosimilars Market by Type
 4.1 Biosimilars Market Overview Snapshot and Growth Engine
 4.2 Biosimilars Market Overview
 4.3 Recombinant non-glycosylated proteins
    
     human growth hormones
     Granulocyte colony-stimulating factor (g-csf)
     Interferons
     Insulin
    
     (human growth hormones
  4.3.1 Introduction and Market Overview
  4.3.2 Historic and Forecasted Market Size (2016-2028F)
  4.3.3 Key Market Trends, Growth Factors and Opportunities
  4.3.4 Recombinant non-glycosylated proteins
    
     human growth hormones
     Granulocyte colony-stimulating factor (g-csf)
     Interferons
     Insulin
    
     (human growth hormones: Grographic Segmentation
 4.4 Granulocyte colony-stimulating factor (g-csf)
  4.4.1 Introduction and Market Overview
  4.4.2 Historic and Forecasted Market Size (2016-2028F)
  4.4.3 Key Market Trends, Growth Factors and Opportunities
  4.4.4 Granulocyte colony-stimulating factor (g-csf): Grographic Segmentation
 4.5 Interferons
  4.5.1 Introduction and Market Overview
  4.5.2 Historic and Forecasted Market Size (2016-2028F)
  4.5.3 Key Market Trends, Growth Factors and Opportunities
  4.5.4 Interferons: Grographic Segmentation
 4.6 Insulin)
  4.6.1 Introduction and Market Overview
  4.6.2 Historic and Forecasted Market Size (2016-2028F)
  4.6.3 Key Market Trends, Growth Factors and Opportunities
  4.6.4 Insulin) : Grographic Segmentation
 4.7 human growth hormones
  4.7.1 Introduction and Market Overview
  4.7.2 Historic and Forecasted Market Size (2016-2028F)
  4.7.3 Key Market Trends, Growth Factors and Opportunities
  4.7.4 human growth hormones: Grographic Segmentation
 4.8 Granulocyte colony-stimulating factor (g-csf)
  4.8.1 Introduction and Market Overview
  4.8.2 Historic and Forecasted Market Size (2016-2028F)
  4.8.3 Key Market Trends, Growth Factors and Opportunities
  4.8.4 Granulocyte colony-stimulating factor (g-csf): Grographic Segmentation
 4.9 Interferons
  4.9.1 Introduction and Market Overview
  4.9.2 Historic and Forecasted Market Size (2016-2028F)
  4.9.3 Key Market Trends, Growth Factors and Opportunities
  4.9.4 Interferons: Grographic Segmentation
 4.10 Insulin
  4.10.1 Introduction and Market Overview
  4.10.2 Historic and Forecasted Market Size (2016-2028F)
  4.10.3 Key Market Trends, Growth Factors and Opportunities
  4.10.4 Insulin: Grographic Segmentation
 4.11 Recombinant glycosylated proteins
    
     erythropoietin
     Monoclonal antibodies
     Follitropin
    
     (erythropoietin
  4.11.1 Introduction and Market Overview
  4.11.2 Historic and Forecasted Market Size (2016-2028F)
  4.11.3 Key Market Trends, Growth Factors and Opportunities
  4.11.4 Recombinant glycosylated proteins
    
     erythropoietin
     Monoclonal antibodies
     Follitropin
    
     (erythropoietin: Grographic Segmentation
 4.12 Monoclonal antibodies
  4.12.1 Introduction and Market Overview
  4.12.2 Historic and Forecasted Market Size (2016-2028F)
  4.12.3 Key Market Trends, Growth Factors and Opportunities
  4.12.4 Monoclonal antibodies: Grographic Segmentation
 4.13 Follitropin)
  4.13.1 Introduction and Market Overview
  4.13.2 Historic and Forecasted Market Size (2016-2028F)
  4.13.3 Key Market Trends, Growth Factors and Opportunities
  4.13.4 Follitropin) : Grographic Segmentation
 4.14 erythropoietin
  4.14.1 Introduction and Market Overview
  4.14.2 Historic and Forecasted Market Size (2016-2028F)
  4.14.3 Key Market Trends, Growth Factors and Opportunities
  4.14.4 erythropoietin: Grographic Segmentation
 4.15 Monoclonal antibodies
  4.15.1 Introduction and Market Overview
  4.15.2 Historic and Forecasted Market Size (2016-2028F)
  4.15.3 Key Market Trends, Growth Factors and Opportunities
  4.15.4 Monoclonal antibodies: Grographic Segmentation
 4.16 Follitropin
  4.16.1 Introduction and Market Overview
  4.16.2 Historic and Forecasted Market Size (2016-2028F)
  4.16.3 Key Market Trends, Growth Factors and Opportunities
  4.16.4 Follitropin: Grographic Segmentation

Chapter 5: Biosimilars Market by Application
 5.1 Biosimilars Market Overview Snapshot and Growth Engine
 5.2 Biosimilars Market Overview
 5.3 Blood Disorders
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2016-2028F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Blood Disorders: Grographic Segmentation
 5.4 Growth Hormonal Deficiency
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2016-2028F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Growth Hormonal Deficiency: Grographic Segmentation
 5.5 Chronic and Autoimmune Disorders
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2016-2028F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Chronic and Autoimmune Disorders: Grographic Segmentation
 5.6 Oncology
  5.6.1 Introduction and Market Overview
  5.6.2 Historic and Forecasted Market Size (2016-2028F)
  5.6.3 Key Market Trends, Growth Factors and Opportunities
  5.6.4 Oncology: Grographic Segmentation
 5.7 and Other Applications
  5.7.1 Introduction and Market Overview
  5.7.2 Historic and Forecasted Market Size (2016-2028F)
  5.7.3 Key Market Trends, Growth Factors and Opportunities
  5.7.4 and Other Applications: Grographic Segmentation

Chapter 6: Company Profiles and Competitive Analysis
 6.1 Competitive Landscape
  6.1.1 Competitive Positioning
  6.1.2 Biosimilars Sales and Market Share By Players
  6.1.3 Industry BCG Matrix
  6.1.4 Ansoff Matrix
  6.1.5 Biosimilars Industry Concentration Ratio (CR5 and HHI)
  6.1.6 Top 5 Biosimilars Players Market Share
  6.1.7 Mergers and Acquisitions
  6.1.8 Business Strategies By Top Players
 6.2 NOVARTIS AG (SWITZERLAND)
  6.2.1 Company Overview
  6.2.2 Key Executives
  6.2.3 Company Snapshot
  6.2.4 Operating Business Segments
  6.2.5 Product Portfolio
  6.2.6 Business Performance
  6.2.7 Key Strategic Moves and Recent Developments
  6.2.8 SWOT Analysis
 6.3 PFIZER INC. (US)
 6.4 DR. REDDY’S LABORATORIES LTD. (INDIA)
 6.5 AMGEN INC. (US)
 6.6 ELI LILLY AND COMPANY (US)
 6.7 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
 6.8 FRESENIUS SE & CO. KGAA (GERMANY)
 6.9 STADA ARZNEIMITTEL AG (GERMANY)
 6.10 BOEHRINGER INGELHEIM (GERMANY)
 6.11 GEDEON RICHTER PLC (HUNGARY)
 6.12 CELLTRION (SOUTH KOREA)
 6.13 SAMSUNG BIOLOGICS (SOUTH KOREA)
 6.14 COHERUS BIOSCIENCES (US)
 6.15 BIOCON LIMITED (INDIA)
 6.16 VIATRIS INC. (US)
 6.17 AMEGA BIOTECH (ARGENTINA)
 6.18 APOTEX INC. (CANADA)
 6.19 BIOCAD (RUSSIA)
 6.20 MABXIENCE (SPAIN)
 6.21 PROBIOMED S.A. DE C.V. (MEXICO)
 6.22 FUJIFILM KYOWA KIRIN BIOLOGICS CO. LTD. (JAPAN)
 6.23 INTAS PHARMACEUTICALS LTD. (INDIA)
 6.24 THERMEX (UK)
 6.25 RELIANCE LIFE SCIENCES (INDIA)
 6.26 KASHIV BIOSCIENCES (US)

Chapter 7: Global Biosimilars Market Analysis, Insights and Forecast, 2016-2028
 7.1 Market Overview
 7.2 Historic and Forecasted Market Size By Type
  7.2.1 Recombinant non-glycosylated proteins
    
     human growth hormones
     Granulocyte colony-stimulating factor (g-csf)
     Interferons
     Insulin
    
     (human growth hormones
  7.2.2 Granulocyte colony-stimulating factor (g-csf)
  7.2.3 Interferons
  7.2.4 Insulin)
  7.2.5 human growth hormones
  7.2.6 Granulocyte colony-stimulating factor (g-csf)
  7.2.7 Interferons
  7.2.8 Insulin
  7.2.9 Recombinant glycosylated proteins
    
     erythropoietin
     Monoclonal antibodies
     Follitropin
    
     (erythropoietin
  7.2.10 Monoclonal antibodies
  7.2.11 Follitropin)
  7.2.12 erythropoietin
  7.2.13 Monoclonal antibodies
  7.2.14 Follitropin
 7.3 Historic and Forecasted Market Size By Application
  7.3.1 Blood Disorders
  7.3.2 Growth Hormonal Deficiency
  7.3.3 Chronic and Autoimmune Disorders
  7.3.4 Oncology
  7.3.5 and Other Applications

Chapter 8: North America Biosimilars Market Analysis, Insights and Forecast, 2016-2028
 8.1 Key Market Trends, Growth Factors and Opportunities
 8.2 Impact of Covid-19
 8.3 Key Players
 8.4 Key Market Trends, Growth Factors and Opportunities
 8.4 Historic and Forecasted Market Size By Type
  8.4.1 Recombinant non-glycosylated proteins
    
     human growth hormones
     Granulocyte colony-stimulating factor (g-csf)
     Interferons
     Insulin
    
     (human growth hormones
  8.4.2 Granulocyte colony-stimulating factor (g-csf)
  8.4.3 Interferons
  8.4.4 Insulin)
  8.4.5 human growth hormones
  8.4.6 Granulocyte colony-stimulating factor (g-csf)
  8.4.7 Interferons
  8.4.8 Insulin
  8.4.9 Recombinant glycosylated proteins
    
     erythropoietin
     Monoclonal antibodies
     Follitropin
    
     (erythropoietin
  8.4.10 Monoclonal antibodies
  8.4.11 Follitropin)
  8.4.12 erythropoietin
  8.4.13 Monoclonal antibodies
  8.4.14 Follitropin
 8.5 Historic and Forecasted Market Size By Application
  8.5.1 Blood Disorders
  8.5.2 Growth Hormonal Deficiency
  8.5.3 Chronic and Autoimmune Disorders
  8.5.4 Oncology
  8.5.5 and Other Applications
 8.6 Historic and Forecast Market Size by Country
  8.6.1 U.S.
  8.6.2 Canada
  8.6.3 Mexico

Chapter 9: Europe Biosimilars Market Analysis, Insights and Forecast, 2016-2028
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Type
  9.4.1 Recombinant non-glycosylated proteins
    
     human growth hormones
     Granulocyte colony-stimulating factor (g-csf)
     Interferons
     Insulin
    
     (human growth hormones
  9.4.2 Granulocyte colony-stimulating factor (g-csf)
  9.4.3 Interferons
  9.4.4 Insulin)
  9.4.5 human growth hormones
  9.4.6 Granulocyte colony-stimulating factor (g-csf)
  9.4.7 Interferons
  9.4.8 Insulin
  9.4.9 Recombinant glycosylated proteins
    
     erythropoietin
     Monoclonal antibodies
     Follitropin
    
     (erythropoietin
  9.4.10 Monoclonal antibodies
  9.4.11 Follitropin)
  9.4.12 erythropoietin
  9.4.13 Monoclonal antibodies
  9.4.14 Follitropin
 9.5 Historic and Forecasted Market Size By Application
  9.5.1 Blood Disorders
  9.5.2 Growth Hormonal Deficiency
  9.5.3 Chronic and Autoimmune Disorders
  9.5.4 Oncology
  9.5.5 and Other Applications
 9.6 Historic and Forecast Market Size by Country
  9.6.1 Germany
  9.6.2 U.K.
  9.6.3 France
  9.6.4 Italy
  9.6.5 Russia
  9.6.6 Spain

Chapter 10: Asia-Pacific Biosimilars Market Analysis, Insights and Forecast, 2016-2028
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Type
  10.4.1 Recombinant non-glycosylated proteins
    
     human growth hormones
     Granulocyte colony-stimulating factor (g-csf)
     Interferons
     Insulin
    
     (human growth hormones
  10.4.2 Granulocyte colony-stimulating factor (g-csf)
  10.4.3 Interferons
  10.4.4 Insulin)
  10.4.5 human growth hormones
  10.4.6 Granulocyte colony-stimulating factor (g-csf)
  10.4.7 Interferons
  10.4.8 Insulin
  10.4.9 Recombinant glycosylated proteins
    
     erythropoietin
     Monoclonal antibodies
     Follitropin
    
     (erythropoietin
  10.4.10 Monoclonal antibodies
  10.4.11 Follitropin)
  10.4.12 erythropoietin
  10.4.13 Monoclonal antibodies
  10.4.14 Follitropin
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Blood Disorders
  10.5.2 Growth Hormonal Deficiency
  10.5.3 Chronic and Autoimmune Disorders
  10.5.4 Oncology
  10.5.5 and Other Applications
 10.6 Historic and Forecast Market Size by Country
  10.6.1 China
  10.6.2 India
  10.6.3 Japan
  10.6.4 Southeast Asia

Chapter 11: South America Biosimilars Market Analysis, Insights and Forecast, 2016-2028
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Type
  11.4.1 Recombinant non-glycosylated proteins
    
     human growth hormones
     Granulocyte colony-stimulating factor (g-csf)
     Interferons
     Insulin
    
     (human growth hormones
  11.4.2 Granulocyte colony-stimulating factor (g-csf)
  11.4.3 Interferons
  11.4.4 Insulin)
  11.4.5 human growth hormones
  11.4.6 Granulocyte colony-stimulating factor (g-csf)
  11.4.7 Interferons
  11.4.8 Insulin
  11.4.9 Recombinant glycosylated proteins
    
     erythropoietin
     Monoclonal antibodies
     Follitropin
    
     (erythropoietin
  11.4.10 Monoclonal antibodies
  11.4.11 Follitropin)
  11.4.12 erythropoietin
  11.4.13 Monoclonal antibodies
  11.4.14 Follitropin
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Blood Disorders
  11.5.2 Growth Hormonal Deficiency
  11.5.3 Chronic and Autoimmune Disorders
  11.5.4 Oncology
  11.5.5 and Other Applications
 11.6 Historic and Forecast Market Size by Country
  11.6.1 Brazil
  11.6.2 Argentina

Chapter 12: Middle East & Africa Biosimilars Market Analysis, Insights and Forecast, 2016-2028
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Type
  12.4.1 Recombinant non-glycosylated proteins
    
     human growth hormones
     Granulocyte colony-stimulating factor (g-csf)
     Interferons
     Insulin
    
     (human growth hormones
  12.4.2 Granulocyte colony-stimulating factor (g-csf)
  12.4.3 Interferons
  12.4.4 Insulin)
  12.4.5 human growth hormones
  12.4.6 Granulocyte colony-stimulating factor (g-csf)
  12.4.7 Interferons
  12.4.8 Insulin
  12.4.9 Recombinant glycosylated proteins
    
     erythropoietin
     Monoclonal antibodies
     Follitropin
    
     (erythropoietin
  12.4.10 Monoclonal antibodies
  12.4.11 Follitropin)
  12.4.12 erythropoietin
  12.4.13 Monoclonal antibodies
  12.4.14 Follitropin
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Blood Disorders
  12.5.2 Growth Hormonal Deficiency
  12.5.3 Chronic and Autoimmune Disorders
  12.5.4 Oncology
  12.5.5 and Other Applications
 12.6 Historic and Forecast Market Size by Country
  12.6.1 Saudi Arabia
  12.6.2 South Africa

Chapter 13 Investment Analysis

Chapter 14 Analyst Viewpoint and Conclusion

LIST OF TABLES

TABLE 001. EXECUTIVE SUMMARY
TABLE 002. BIOSIMILARS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. BIOSIMILARS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. BIOSIMILARS MARKET COMPETITIVE RIVALRY
TABLE 005. BIOSIMILARS MARKET THREAT OF NEW ENTRANTS
TABLE 006. BIOSIMILARS MARKET THREAT OF SUBSTITUTES
TABLE 007. BIOSIMILARS MARKET BY TYPE
TABLE 008. RECOMBINANT NON-GLYCOSYLATED PROTEINS
    
     HUMAN GROWTH HORMONES
     GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF)
     INTERFERONS
     INSULIN
    
     (HUMAN GROWTH HORMONES MARKET OVERVIEW (2016-2028)
TABLE 009. GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) MARKET OVERVIEW (2016-2028)
TABLE 010. INTERFERONS MARKET OVERVIEW (2016-2028)
TABLE 011. INSULIN) MARKET OVERVIEW (2016-2028)
TABLE 012. HUMAN GROWTH HORMONES MARKET OVERVIEW (2016-2028)
TABLE 013. GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) MARKET OVERVIEW (2016-2028)
TABLE 014. INTERFERONS MARKET OVERVIEW (2016-2028)
TABLE 015. INSULIN MARKET OVERVIEW (2016-2028)
TABLE 016. RECOMBINANT GLYCOSYLATED PROTEINS
    
     ERYTHROPOIETIN
     MONOCLONAL ANTIBODIES
     FOLLITROPIN
    
     (ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
TABLE 017. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
TABLE 018. FOLLITROPIN) MARKET OVERVIEW (2016-2028)
TABLE 019. ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
TABLE 020. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
TABLE 021. FOLLITROPIN MARKET OVERVIEW (2016-2028)
TABLE 022. BIOSIMILARS MARKET BY APPLICATION
TABLE 023. BLOOD DISORDERS MARKET OVERVIEW (2016-2028)
TABLE 024. GROWTH HORMONAL DEFICIENCY MARKET OVERVIEW (2016-2028)
TABLE 025. CHRONIC AND AUTOIMMUNE DISORDERS MARKET OVERVIEW (2016-2028)
TABLE 026. ONCOLOGY MARKET OVERVIEW (2016-2028)
TABLE 027. AND OTHER APPLICATIONS MARKET OVERVIEW (2016-2028)
TABLE 028. NORTH AMERICA BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 029. NORTH AMERICA BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 030. N BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 031. EUROPE BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 032. EUROPE BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 033. BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 034. ASIA PACIFIC BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 035. ASIA PACIFIC BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 036. BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 037. MIDDLE EAST & AFRICA BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 038. MIDDLE EAST & AFRICA BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 039. BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 040. SOUTH AMERICA BIOSIMILARS MARKET, BY TYPE (2016-2028)
TABLE 041. SOUTH AMERICA BIOSIMILARS MARKET, BY APPLICATION (2016-2028)
TABLE 042. BIOSIMILARS MARKET, BY COUNTRY (2016-2028)
TABLE 043. NOVARTIS AG (SWITZERLAND): SNAPSHOT
TABLE 044. NOVARTIS AG (SWITZERLAND): BUSINESS PERFORMANCE
TABLE 045. NOVARTIS AG (SWITZERLAND): PRODUCT PORTFOLIO
TABLE 046. NOVARTIS AG (SWITZERLAND): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 046. PFIZER INC. (US): SNAPSHOT
TABLE 047. PFIZER INC. (US): BUSINESS PERFORMANCE
TABLE 048. PFIZER INC. (US): PRODUCT PORTFOLIO
TABLE 049. PFIZER INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 049. DR. REDDY’S LABORATORIES LTD. (INDIA): SNAPSHOT
TABLE 050. DR. REDDY’S LABORATORIES LTD. (INDIA): BUSINESS PERFORMANCE
TABLE 051. DR. REDDY’S LABORATORIES LTD. (INDIA): PRODUCT PORTFOLIO
TABLE 052. DR. REDDY’S LABORATORIES LTD. (INDIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 052. AMGEN INC. (US): SNAPSHOT
TABLE 053. AMGEN INC. (US): BUSINESS PERFORMANCE
TABLE 054. AMGEN INC. (US): PRODUCT PORTFOLIO
TABLE 055. AMGEN INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 055. ELI LILLY AND COMPANY (US): SNAPSHOT
TABLE 056. ELI LILLY AND COMPANY (US): BUSINESS PERFORMANCE
TABLE 057. ELI LILLY AND COMPANY (US): PRODUCT PORTFOLIO
TABLE 058. ELI LILLY AND COMPANY (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 058. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): SNAPSHOT
TABLE 059. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): BUSINESS PERFORMANCE
TABLE 060. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): PRODUCT PORTFOLIO
TABLE 061. TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 061. FRESENIUS SE & CO. KGAA (GERMANY): SNAPSHOT
TABLE 062. FRESENIUS SE & CO. KGAA (GERMANY): BUSINESS PERFORMANCE
TABLE 063. FRESENIUS SE & CO. KGAA (GERMANY): PRODUCT PORTFOLIO
TABLE 064. FRESENIUS SE & CO. KGAA (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 064. STADA ARZNEIMITTEL AG (GERMANY): SNAPSHOT
TABLE 065. STADA ARZNEIMITTEL AG (GERMANY): BUSINESS PERFORMANCE
TABLE 066. STADA ARZNEIMITTEL AG (GERMANY): PRODUCT PORTFOLIO
TABLE 067. STADA ARZNEIMITTEL AG (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 067. BOEHRINGER INGELHEIM (GERMANY): SNAPSHOT
TABLE 068. BOEHRINGER INGELHEIM (GERMANY): BUSINESS PERFORMANCE
TABLE 069. BOEHRINGER INGELHEIM (GERMANY): PRODUCT PORTFOLIO
TABLE 070. BOEHRINGER INGELHEIM (GERMANY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 070. GEDEON RICHTER PLC (HUNGARY): SNAPSHOT
TABLE 071. GEDEON RICHTER PLC (HUNGARY): BUSINESS PERFORMANCE
TABLE 072. GEDEON RICHTER PLC (HUNGARY): PRODUCT PORTFOLIO
TABLE 073. GEDEON RICHTER PLC (HUNGARY): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 073. CELLTRION (SOUTH KOREA): SNAPSHOT
TABLE 074. CELLTRION (SOUTH KOREA): BUSINESS PERFORMANCE
TABLE 075. CELLTRION (SOUTH KOREA): PRODUCT PORTFOLIO
TABLE 076. CELLTRION (SOUTH KOREA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 076. SAMSUNG BIOLOGICS (SOUTH KOREA): SNAPSHOT
TABLE 077. SAMSUNG BIOLOGICS (SOUTH KOREA): BUSINESS PERFORMANCE
TABLE 078. SAMSUNG BIOLOGICS (SOUTH KOREA): PRODUCT PORTFOLIO
TABLE 079. SAMSUNG BIOLOGICS (SOUTH KOREA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 079. COHERUS BIOSCIENCES (US): SNAPSHOT
TABLE 080. COHERUS BIOSCIENCES (US): BUSINESS PERFORMANCE
TABLE 081. COHERUS BIOSCIENCES (US): PRODUCT PORTFOLIO
TABLE 082. COHERUS BIOSCIENCES (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 082. BIOCON LIMITED (INDIA): SNAPSHOT
TABLE 083. BIOCON LIMITED (INDIA): BUSINESS PERFORMANCE
TABLE 084. BIOCON LIMITED (INDIA): PRODUCT PORTFOLIO
TABLE 085. BIOCON LIMITED (INDIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 085. VIATRIS INC. (US): SNAPSHOT
TABLE 086. VIATRIS INC. (US): BUSINESS PERFORMANCE
TABLE 087. VIATRIS INC. (US): PRODUCT PORTFOLIO
TABLE 088. VIATRIS INC. (US): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 088. AMEGA BIOTECH (ARGENTINA): SNAPSHOT
TABLE 089. AMEGA BIOTECH (ARGENTINA): BUSINESS PERFORMANCE
TABLE 090. AMEGA BIOTECH (ARGENTINA): PRODUCT PORTFOLIO
TABLE 091. AMEGA BIOTECH (ARGENTINA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 091. APOTEX INC. (CANADA): SNAPSHOT
TABLE 092. APOTEX INC. (CANADA): BUSINESS PERFORMANCE
TABLE 093. APOTEX INC. (CANADA): PRODUCT PORTFOLIO
TABLE 094. APOTEX INC. (CANADA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 094. BIOCAD (RUSSIA): SNAPSHOT
TABLE 095. BIOCAD (RUSSIA): BUSINESS PERFORMANCE
TABLE 096. BIOCAD (RUSSIA): PRODUCT PORTFOLIO
TABLE 097. BIOCAD (RUSSIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 097. MABXIENCE (SPAIN): SNAPSHOT
TABLE 098. MABXIENCE (SPAIN): BUSINESS PERFORMANCE
TABLE 099. MABXIENCE (SPAIN): PRODUCT PORTFOLIO
TABLE 100. MABXIENCE (SPAIN): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 100. PROBIOMED S.A. DE C.V. (MEXICO): SNAPSHOT
TABLE 101. PROBIOMED S.A. DE C.V. (MEXICO): BUSINESS PERFORMANCE
TABLE 102. PROBIOMED S.A. DE C.V. (MEXICO): PRODUCT PORTFOLIO
TABLE 103. PROBIOMED S.A. DE C.V. (MEXICO): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 103. FUJIFILM KYOWA KIRIN BIOLOGICS CO. LTD. (JAPAN): SNAPSHOT
TABLE 104. FUJIFILM KYOWA KIRIN BIOLOGICS CO. LTD. (JAPAN): BUSINESS PERFORMANCE
TABLE 105. FUJIFILM KYOWA KIRIN BIOLOGICS CO. LTD. (JAPAN): PRODUCT PORTFOLIO
TABLE 106. FUJIFILM KYOWA KIRIN BIOLOGICS CO. LTD. (JAPAN): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 106. INTAS PHARMACEUTICALS LTD. (INDIA): SNAPSHOT
TABLE 107. INTAS PHARMACEUTICALS LTD. (INDIA): BUSINESS PERFORMANCE
TABLE 108. INTAS PHARMACEUTICALS LTD. (INDIA): PRODUCT PORTFOLIO
TABLE 109. INTAS PHARMACEUTICALS LTD. (INDIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 109. THERMEX (UK): SNAPSHOT
TABLE 110. THERMEX (UK): BUSINESS PERFORMANCE
TABLE 111. THERMEX (UK): PRODUCT PORTFOLIO
TABLE 112. THERMEX (UK): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 112. RELIANCE LIFE SCIENCES (INDIA): SNAPSHOT
TABLE 113. RELIANCE LIFE SCIENCES (INDIA): BUSINESS PERFORMANCE
TABLE 114. RELIANCE LIFE SCIENCES (INDIA): PRODUCT PORTFOLIO
TABLE 115. RELIANCE LIFE SCIENCES (INDIA): KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 115. KASHIV BIOSCIENCES (US): SNAPSHOT
TABLE 116. KASHIV BIOSCIENCES (US): BUSINESS PERFORMANCE
TABLE 117. KASHIV BIOSCIENCES (US): PRODUCT PORTFOLIO
TABLE 118. KASHIV BIOSCIENCES (US): KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. BIOSIMILARS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. BIOSIMILARS MARKET OVERVIEW BY TYPE
FIGURE 012. RECOMBINANT NON-GLYCOSYLATED PROTEINS
    
     HUMAN GROWTH HORMONES
     GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF)
     INTERFERONS
     INSULIN
    
     (HUMAN GROWTH HORMONES MARKET OVERVIEW (2016-2028)
FIGURE 013. GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) MARKET OVERVIEW (2016-2028)
FIGURE 014. INTERFERONS MARKET OVERVIEW (2016-2028)
FIGURE 015. INSULIN) MARKET OVERVIEW (2016-2028)
FIGURE 016. HUMAN GROWTH HORMONES MARKET OVERVIEW (2016-2028)
FIGURE 017. GRANULOCYTE COLONY-STIMULATING FACTOR (G-CSF) MARKET OVERVIEW (2016-2028)
FIGURE 018. INTERFERONS MARKET OVERVIEW (2016-2028)
FIGURE 019. INSULIN MARKET OVERVIEW (2016-2028)
FIGURE 020. RECOMBINANT GLYCOSYLATED PROTEINS
    
     ERYTHROPOIETIN
     MONOCLONAL ANTIBODIES
     FOLLITROPIN
    
     (ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
FIGURE 021. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
FIGURE 022. FOLLITROPIN) MARKET OVERVIEW (2016-2028)
FIGURE 023. ERYTHROPOIETIN MARKET OVERVIEW (2016-2028)
FIGURE 024. MONOCLONAL ANTIBODIES MARKET OVERVIEW (2016-2028)
FIGURE 025. FOLLITROPIN MARKET OVERVIEW (2016-2028)
FIGURE 026. BIOSIMILARS MARKET OVERVIEW BY APPLICATION
FIGURE 027. BLOOD DISORDERS MARKET OVERVIEW (2016-2028)
FIGURE 028. GROWTH HORMONAL DEFICIENCY MARKET OVERVIEW (2016-2028)
FIGURE 029. CHRONIC AND AUTOIMMUNE DISORDERS MARKET OVERVIEW (2016-2028)
FIGURE 030. ONCOLOGY MARKET OVERVIEW (2016-2028)
FIGURE 031. AND OTHER APPLICATIONS MARKET OVERVIEW (2016-2028)
FIGURE 032. NORTH AMERICA BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 033. EUROPE BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 034. ASIA PACIFIC BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 035. MIDDLE EAST & AFRICA BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 036. SOUTH AMERICA BIOSIMILARS MARKET OVERVIEW BY COUNTRY (2016-2028)